期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 20, 期 7, 页码 961-972出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2011.579560
关键词
INCB018424; JAK2 inhibitors; JAK2 V617F; lestaurtinib; myeloproliferative neoplasias; ruxolitinib; tasocitinib; TG101348
资金
- Incyte
- AstraZeneca
- Celgene
- SBIO
- Exelixis
- Gilead
- Eli Lilly and Co.
- NS-Pharma Roche
- Geron
- AB Science
- Bristol-Myers Squibb
Areas covered: Several JAK2 kinase inhibitors are being tested in clinical trials for patients with MPNs. In PMF trials, JAK2 inhibitors have been shown to produce rapid reductions in spleen size and marked improvements in constitutional symptoms and quality of life. In ET and/or PV, JAK2 inhibitors normalize hematocrit, platelets and WBC, and spleen size in a large number of patients that are resistant or intolerant to hydroxyurea. JAK2 inhibitors are not specific for the JAK2V617F mutant protein. Rather, they inhibit the JAK2-- signal transducer and activator of transcription (STAT) pathway and therefore any patient with MPN may benefit from therapy regardless of JAK2 mutational status. Expert opinion: JAK2 inhibitors induce clinically relevant responses in a large proportion of patients with MPNs. Because JAK kinase activation underlies the pathogenesis of other disorders, such as autoimmune and rheumatological disorders, the paradigm of JAK inhibition may translate into novel therapies for a variety of human diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据